GET DAILY SIGNALSWhy Is Precigen (PGEN) Stock Down -25.79% Today?
Key Takeaways
- Shares of PGEN fell roughly 25.79% to about $5.15, down from a prior close of $6.94.
- The primary catalyst was the FDA's accelerated approval of Inovio's Voceryq, a direct competitor to Precigen's only commercial drug, PAPZIMEOS.
- Secondary pressure came from an already-soft technical backdrop: PGEN fell 19% in October, and the gap-down resumed that correction.
- The news broke Precigen's market exclusivity in recurrent respiratory papillomatosis (RRP), a rare disease that drives the vast majority of its revenue.
- Traders are now focused on Precigen's third-quarter earnings on November 4 and whether the stock can reclaim key technical levels.
- For deeper analysis, explore Price Targets, Earnings, and Forecast pages on this ticker.
- You can also track the strongest-performing strategies on Tickeron's Trending AI Robots page.
Opening Summary
Precigen, Inc. (PGEN) is a commercial-stage biopharmaceutical company focused on precision gene and cell therapies, best known for PAPZIMEOS, the first FDA-approved treatment for adult recurrent respiratory papillomatosis (RRP). On Monday, the stock plunged roughly 25.79%, trading near $5.15 after closing the prior session at $6.94. The selloff was a direct market reaction to the FDA's approval of a competing RRP therapy, which erodes the exclusivity premium that had underpinned Precigen's valuation.
FDA Approval of Inovio's Voceryq Ends Precigen's RRP Monopoly
The decisive catalyst was regulatory: on Friday, the U.S. Food and Drug Administration granted accelerated approval to Inovio Pharmaceuticals' (INO) Voceryq, a plasmid DNA-based immunotherapy for adults with RRP. RRP is the rare HPV-related disease that causes recurring, wart-like growths in the airways — the same condition PAPZIMEOS treats.
For Precigen, this is a structural shift, not a routine headline. PAPZIMEOS is the company's only approved product and accounted for roughly $74.7 million of the company's approximately $78.2 million in first-half 2026 revenue. Investors had been paying for a franchise with no direct rival. Voceryq's approval removes that "single-player" premium, even though Inovio has said shipments won't begin for roughly 60 days and full commercial launch is expected in early 2027.
The competitive picture is nuanced. PAPZIMEOS holds a commercial head start, having launched after its August 2025 approval and generated $53.1 million in second-quarter product revenue. Precigen also cites stronger efficacy data — about a 51% surgery-free response rate versus roughly 27% in Inovio's open-label study. Still, the market moved first to reprice the loss of exclusivity, and Inovio's shares surged more than 300% after hours on the same news.
Market Context and Trading Activity
The move was amplified by volume and technical positioning. Precigen's regular-session trading was already elevated — Friday's close of $6.94, up 4.5%, came on volume well above the stock's typical daily average — and the after-hours liquidation pushed shares into the low-$5 range. That drop landed almost precisely on the 200-day moving average, near $5.26, which also coincides with a deep retracement of the year's advance from roughly $3.04 to a 52-week high of $8.98.
The decline was stock-specific rather than a broad-market event. The move diverged sharply from Inovio's rally and was driven by company-level competitive dynamics rather than sector-wide biotech weakness. Shares were already correcting before the news — off nearly 19% over the prior month — so the gap-down extended an existing pullback rather than starting a fresh one.
What Comes Next for PGEN
All eyes now turn to Precigen's third-quarter 2026 results on November 4, when management is expected to update PAPZIMEOS revenue momentum and provide portfolio guidance. A strong print could help investors reassess whether the selloff overstates the near-term competitive threat, given Voceryq's delayed commercial launch and the confirmatory trials Inovio must still complete.
Key risks remain. If the stock fails to reclaim the roughly $6.50-to-$6.94 gap and the 50-day average near $7.20, the technical picture could weaken further, with support near $5.25-to-$5.35 and a potential path toward the low-$4 range. Conversely, a decisive recovery would suggest the market has absorbed the competitive scare. Beyond RRP, investors will watch Precigen's AdenoVerse platform and its PRGN-2009 program in HPV-associated cancers for catalysts that could diversify the revenue story away from a single product.
Trending AI Robots
Tickeron's Trending AI Robots page curates the platform's strongest-performing AI trading bots under current market conditions. Tickeron offers hundreds of AI-driven bots covering thousands of tickers, each varying by strategy, timeframe, performance metrics, and traded symbols. Only the top performers are featured in this section, helping traders discover data-driven approaches tailored to live market environments. Explore the page to see which strategies are currently leading.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PGEN's Indicator enters downward trend
The Aroon Indicator for PGEN entered a downward trend on November 02, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 223 similar instances where the Aroon Indicator formed such a pattern. In 194 of the 223 cases the stock moved lower. This puts the odds of a downward move at 87%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PGEN as a result. In 81 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for PGEN turned negative on October 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 43 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
PGEN moved below its 50-day moving average on October 15, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for PGEN crossed bearishly below the 50-day moving average on October 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for PGEN's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 63 of 70 cases where PGEN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
Following a +14.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where PGEN advanced for three days, in 206 of 241 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
PGEN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. PGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 48 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (43.136) is normal, around the industry mean (3.104). P/E Ratio (-4.907) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (32.258) is also within normal values, averaging (439.647).
The Tickeron Profit vs. Risk Rating rating for this company is 98 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biotechnology company, which engages in the research and development of synthetic biology technologies.
Industry Biotechnology
Advertisement